885 related articles for article (PubMed ID: 28476164)
21. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
Yan M; Li G; An J
Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
[TBL] [Abstract][Full Text] [Related]
22. High levels of β-catenin signaling reduce osteogenic differentiation of stem cells in inflammatory microenvironments through inhibition of the noncanonical Wnt pathway.
Liu N; Shi S; Deng M; Tang L; Zhang G; Liu N; Ding B; Liu W; Liu Y; Shi H; Liu L; Jin Y
J Bone Miner Res; 2011 Sep; 26(9):2082-95. PubMed ID: 21638320
[TBL] [Abstract][Full Text] [Related]
23. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.
Martins-Neves SR; Paiva-Oliveira DI; Fontes-Ribeiro C; Bovée JVMG; Cleton-Jansen AM; Gomes CMF
Cancer Lett; 2018 Feb; 414():1-15. PubMed ID: 29126913
[TBL] [Abstract][Full Text] [Related]
24. Taxifolin curbs NF-κB-mediated Wnt/β-catenin signaling via up-regulating Nrf2 pathway in experimental colon carcinogenesis.
Manigandan K; Manimaran D; Jayaraj RL; Elangovan N; Dhivya V; Kaphle A
Biochimie; 2015 Dec; 119():103-12. PubMed ID: 26482805
[TBL] [Abstract][Full Text] [Related]
25. Biomimetic and Self-Assembled Nanoclusters Targeting β-Catenin for Potent Anticancer Therapy and Enhanced Immunotherapy.
Liu J; Yan J; Yan S; Wang Y; Zhang R; Hou P; He W; Ji M
Nano Lett; 2019 Dec; 19(12):8708-8715. PubMed ID: 31744296
[TBL] [Abstract][Full Text] [Related]
26. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
27. [Screening for Chemical Suppressors of the Wnt/β-catenin Signaling Pathway].
Nishiya N
Yakugaku Zasshi; 2017; 137(2):133-136. PubMed ID: 28154320
[TBL] [Abstract][Full Text] [Related]
28. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.
Krishnamurthy N; Kurzrock R
Cancer Treat Rev; 2018 Jan; 62():50-60. PubMed ID: 29169144
[TBL] [Abstract][Full Text] [Related]
29. Wnt/β-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons.
Mukherjee N; Panda CK
Clin Breast Cancer; 2020 Oct; 20(5):361-370. PubMed ID: 32416986
[TBL] [Abstract][Full Text] [Related]
30. Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells.
Wang Z; Li B; Zhou L; Yu S; Su Z; Song J; Sun Q; Sha O; Wang X; Jiang W; Willert K; Wei L; Carson DA; Lu D
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13150-13155. PubMed ID: 27799526
[TBL] [Abstract][Full Text] [Related]
31. Sevoflurane affects neurogenesis through cell cycle arrest via inhibiting wnt/β-catenin signaling pathway in mouse neural stem cells.
Liu S; Fang F; Song R; Gao X; Jiang M; Cang J
Life Sci; 2018 Sep; 209():34-42. PubMed ID: 30071197
[TBL] [Abstract][Full Text] [Related]
32. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
[TBL] [Abstract][Full Text] [Related]
33. E3 ubiquitin ligase Mule targets β-catenin under conditions of hyperactive Wnt signaling.
Dominguez-Brauer C; Khatun R; Elia AJ; Thu KL; Ramachandran P; Baniasadi SP; Hao Z; Jones LD; Haight J; Sheng Y; Mak TW
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):E1148-E1157. PubMed ID: 28137882
[TBL] [Abstract][Full Text] [Related]
34. Wnt signaling in cancer.
Zhan T; Rindtorff N; Boutros M
Oncogene; 2017 Mar; 36(11):1461-1473. PubMed ID: 27617575
[TBL] [Abstract][Full Text] [Related]
35. Targeting the canonical Wnt/β-catenin pathway in hematological malignancies.
Ashihara E; Takada T; Maekawa T
Cancer Sci; 2015 Jun; 106(6):665-671. PubMed ID: 25788321
[TBL] [Abstract][Full Text] [Related]
36. Wnt signaling as a therapeutic target for cancer.
Herbst A; Kolligs FT
Methods Mol Biol; 2007; 361():63-91. PubMed ID: 17172707
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives.
Pashirzad M; Shafiee M; Khazaei M; Fiuji H; Ryzhikov M; Soleimanpour S; Hesari A; Avan A; Hassanian SM
J Cell Physiol; 2019 Feb; 234(2):1237-1247. PubMed ID: 30191954
[TBL] [Abstract][Full Text] [Related]
38. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
39. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.
Harb J; Lin PJ; Hao J
Curr Oncol Rep; 2019 Feb; 21(2):12. PubMed ID: 30715618
[TBL] [Abstract][Full Text] [Related]
40. 2,3,6-Trisubstituted quinoxaline derivative, a small molecule inhibitor of the Wnt/beta-catenin signaling pathway, suppresses cell proliferation and enhances radiosensitivity in A549/Wnt2 cells.
Lee SB; Gong YD; Park YI; Dong MS
Biochem Biophys Res Commun; 2013 Feb; 431(4):746-52. PubMed ID: 23348226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
